All In Biotech

Drug Trial Radar · NCT06633718

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

A Phase 3,Multicenter, Randomized, Double-Blind, Positive Control,Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Complicated Intra-abdominal Infections

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 786 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

786

Planned (sponsor's estimate)

Start

Oct 31, 2024

Primary completion

May 30, 2027

Study completion May 30, 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI).

Conditions

  • Intra-abdominal Infections

Interventions

  • Meropenem and PralurbactamDrug

    3g,q8h,120min infusion

  • SalineDrug

    100mL,q8h,60min infusion

  • Ceftazidime-avibactamDrug

    2.5g,q8h,120min infusion

  • MetronidazoleDrug

    0.915g,q8h,60min infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Clinical Response of "Cure" at the Test of Cure (TOC) VisitTime frame: Up to approximately 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.